Phase I Trial of BI 836845 for Various Solid Cancer
- Conditions
- Neoplasms
- Interventions
- Drug: BI 836845
- First Posted Date
- 2011-07-27
- Last Posted Date
- 2016-01-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 61
- Registration Number
- NCT01403974
- Locations
- 🇨🇳
1280.1.88603 Boehringer Ingelheim Investigational Site, Taichung, Taiwan
🇨🇳1280.1.88602 Boehringer Ingelheim Investigational Site, Tainan, Taiwan
🇨🇳1280.1.88601 Boehringer Ingelheim Investigational Site, Taipei, Taiwan
BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)
- First Posted Date
- 2011-07-27
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 48
- Registration Number
- NCT01403948
- Locations
- 🇫🇷
HOP Lyon Sud, Pierre Bénite, France
🇩🇪Asklepios Klinik St. Georg, Hamburg, Germany
🇩🇪Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: BI201335 24WDrug: BI201335Drug: PegIFN/RBVDrug: Bi 201335
- First Posted Date
- 2011-07-22
- Last Posted Date
- 2016-08-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 310
- Registration Number
- NCT01399619
- Locations
- 🇺🇸
1220.19.0013 Boehringer Ingelheim Investigational Site, Philadelphia, Pennsylvania, United States
🇧🇷1220.19.5505 Boehringer Ingelheim Investigational Site, São Paulo, Brazil
🇮🇹1220.19.3901 Boehringer Ingelheim Investigational Site, Antella (fi), Italy
Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2011-07-19
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT01397201
- Locations
- 🇺🇸
1248.6.01019 Boehringer Ingelheim Investigational Site, Baltimore, Maryland, United States
🇺🇸1248.6.01049 Boehringer Ingelheim Investigational Site, Berlin, New Jersey, United States
🇺🇸1248.6.01040 Boehringer Ingelheim Investigational Site, Pittsburgh, Pennsylvania, United States
Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2011-07-19
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 29
- Registration Number
- NCT01397162
- Locations
- 🇺🇸
1248.5.01047 Boehringer Ingelheim Investigational Site, Fountain Valley, California, United States
🇺🇸1248.5.01042 Boehringer Ingelheim Investigational Site, Sarasota, Florida, United States
🇺🇸1248.5.01013 Boehringer Ingelheim Investigational Site, Philadelphia, Pennsylvania, United States
Drug Interaction Study With Rifampicin and Afatinib
- First Posted Date
- 2011-07-18
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 22
- Registration Number
- NCT01396265
- Locations
- 🇩🇪
1200.152.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2011-07-18
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 9
- Registration Number
- NCT01396278
- Locations
- 🇺🇸
1248.7.01035 Boehringer Ingelheim Investigational Site, Aventura, Florida, United States
🇺🇸1248.7.01056 Boehringer Ingelheim Investigational Site, Rolla, Missouri, United States
🇺🇸1248.7.01013 Boehringer Ingelheim Investigational Site, Philadelphia, Pennsylvania, United States
Safety and Efficacy of Empagliflozin (BI 10773) in Type 1 Diabetes Mellitus Patients With or Without Renal Hyperfiltration
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2014-06-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 52
- Registration Number
- NCT01392560
- Locations
- 🇨🇦
1245.46.10001 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada
ADESPI: Adherence to Spiriva® in Patients With COPD (Chronic Obstructive Pulmonary Disease), Measured by Morisky-8 (MMAS-8) Scale, in Routine Medical Practice
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Procedure: Education
- First Posted Date
- 2011-07-06
- Last Posted Date
- 2014-12-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1253
- Registration Number
- NCT01388166
- Locations
- 🇭🇺
Boehringer Ingelheim Investigational Site 55, Cegléd, Hungary
🇭🇺Boehringer Ingelheim Investigational Site 90, Budapest, Hungary
🇸🇰Boehringer Ingelheim Investigational Site 36, Lucenec, Slovakia
Comparison of the Bioavailability of Metformin Between Medium Dose Linagliptin/Metformin Tablets and Medium Dose Glucophage Tablet Given With Linagliptin Tablet
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2011-06-28
- Last Posted Date
- 2014-03-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 58
- Registration Number
- NCT01383356
- Locations
- 🇨🇦
1288.19.1 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada